NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free THAR Stock Alerts $4.84 +0.27 (+5.91%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$4.37▼$5.0350-Day Range$4.48▼$6.9852-Week Range$4.15▼$163.09Volume93,137 shsAverage Volume25,225 shsMarket Capitalization$3.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Tharimmune alerts: Email Address Ad American AlternativeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About Tharimmune Stock (NASDAQ:THAR)Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Read More THAR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THAR Stock News HeadlinesMay 29 at 10:59 AM | finanznachrichten.deTharimmune, Inc.: Tharimmune to Present at 2024 BIO International ConventionMay 29 at 10:59 AM | finance.yahoo.comTharimmune to Present at 2024 BIO International ConventionMay 24, 2024 | investorplace.comWhy Is Tharimmune (THAR) Stock Moving Today?May 24, 2024 | americanbankingnews.comTharimmune (NASDAQ:THAR) Shares Scheduled to Reverse Split on Tuesday, May 28thMay 22, 2024 | msn.comWhy Tharimmune (THAR) Shares Are MovingMay 22, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finance.yahoo.comTharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | americanbankingnews.comTharimmune (NASDAQ:THAR) Trading Up 3.9%May 9, 2024 | investorplace.comTHAR Stock Earnings: Tharimmune Reported Results for Q4 2023May 2, 2024 | finance.yahoo.comStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus ManagementApril 24, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 18, 2024 | morningstar.comTharimmune Inc THARApril 16, 2024 | investing.comTharimmune forms advisory board to guide drug developmentFebruary 21, 2024 | msn.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 20, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseFebruary 20, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finance.yahoo.comTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 9, 2024 | msn.comTharimmune’s Active Common Stock Shares UpdateFebruary 5, 2024 | finance.yahoo.comTharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary CholangitisJanuary 29, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business UpdateDecember 11, 2023 | finance.yahoo.comTharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease PatientsNovember 30, 2023 | finance.yahoo.comTharimmune, Inc. Announces Closing of $11 Million Public OfferingNovember 30, 2023 | msn.comWhy Tharimmune Stock (THAR) Is Down 70% TodayNovember 29, 2023 | msn.comWhy Is Liver Disease Focused Tharimmune Stock Trading Higher Today?November 29, 2023 | marketwatch.comTharimmune Shares Hit 52-Week Low After Public Offering PricesSee More Headlines Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/30/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.23% Return on Assets-128.80% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio4.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book8.07Miscellaneous Outstanding Shares11,790,000Free Float11,511,000Market Cap$57.06 million OptionableNot Optionable Beta1.61 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Randy D. Milby MBA (Age 70)President, Chairman & CEO Comp: $593.75kMr. Sireesh Appajosyula Pharm.D. (Age 48)COO & Director Comp: $584.8kMr. Thomas P. Hess CPA (Age 60)MBA, Chief Financial Officer Key CompetitorsuniQureNASDAQ:QUREXBiotechNASDAQ:XBITPyxis OncologyNASDAQ:PYXSConduit PharmaceuticalsNASDAQ:CDTEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInsidersRandy MilbyBought 1,933 shares on 12/15/2023Total: $14,497.50 ($7.50/share)Randy MilbyBought 666 shares on 11/30/2023Total: $9,990.00 ($15.00/share)View All Insider Transactions THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed in 2024? Tharimmune's stock was trading at $7.6350 on January 1st, 2024. Since then, THAR shares have decreased by 36.6% and is now trading at $4.8401. View the best growth stocks for 2024 here. Are investors shorting Tharimmune? Tharimmune saw a decrease in short interest in May. As of May 15th, there was short interest totaling 20,000 shares, a decrease of 83.2% from the April 30th total of 119,000 shares. Based on an average daily volume of 299,400 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company's stock are short sold. View Tharimmune's Short Interest. When is Tharimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our THAR earnings forecast. How were Tharimmune's earnings last quarter? Tharimmune, Inc. (NASDAQ:THAR) released its earnings results on Thursday, May, 9th. The company reported ($2.85) earnings per share for the quarter. When did Tharimmune's stock split? Tharimmune shares reverse split on the morning of Tuesday, May 28th 2024. The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:THAR) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.